Gender disparity on cigarette smoking among cancer survivors: Results from the National Health Interview Survey.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e24040-e24040
Author(s):  
Changchuan Jiang ◽  
Haowei Wang ◽  
Lei Deng ◽  
Qian Wang ◽  
Xuesong Han ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Cancer Survivors ◽  
Smoking Prevalence ◽  
Smoking Rate ◽  
Current Smoking ◽  
Female Survivors ◽  
History Of ◽  
Interview Survey ◽  
Female Cancer Survivors ◽  
History Of Cancer

e24040 Background: The smoking rate has been declining in the United States. Smoking cessation is a critical part of cancer survivorship care. Males have higher smoking rate than females in the general population. However, it remains unclear if cancer status modified the effect of gender on smoking rates. Methods: To evaluate the long-term pattern of smoking prevalence among female cancer survivors, we used the National Health Interview Survey 2000-2017 to estimate the age-adjusted current smoking rates among cancer survivors and participants without a history of cancer for men and women separately. Multivariable linear regression was used to estimate age-adjusted smoking rate in each group, using the US 2010 Census as the standardization population. We also used multivariable logistic regression to examine the whether cancer history modified the influence of gender on current smoking rate. All statistical analyses were performed with SAS 9.4 and accounted for NHIS survey design. Results: Of 526,547 participants, we identified 32,091 cancer survivors, including 11,642 male and 20,449 female cancer survivors. Male cancer survivors had a slightly lower smoking rates than non-cancer male participants (cancer survivors: 16.2%-29.7% vs non-cancer participants: 16.8%-24.4%; OR = 0.94, 95%CI 0.88-1.00, p = 0.05) after adjusting age and year of survey. However, female cancer survivors had a significant higher prevalence of smoking compared with non-cancer female participants (cancer survivors: 20.1-32.6% vs non-cancer participants: women: 12.8%-20.4%; OR = 1.45, 95%CI 1.38-1.52, p < 0.001) during the same period. The gaps in smoking prevalence between female cancer survivors and male cancer survivors were more significant than the gaps between male non-cancer participants and female non-cancer participants from 2000 to 2017 (p interaction < 0.001). Conclusions: Although more men smoke among people without a history of cancer, female survivors had a higher age-adjusted smoking rate than their male counterparts. Effective smoking cessation interventions need to target female survivors as well as male survivors. A gender-sensitive approach is required to address their specific needs in smoking cessation. [Table: see text]

Transdermal testosterone in female cancer survivors with decreased libido

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 8507-8507 ◽  
Author(s):  
D. L. Barton ◽  
C. Loprinzi ◽  
D. Wender ◽  
R. Dalton ◽  
E. Balcueva ◽  
...  
Keyword(s):  
Cancer Survivors ◽  
Primary Endpoint ◽  
Sexual Desire ◽  
Sexual Functioning ◽  
Phase Iii ◽  
Type I ◽  
History Of ◽  
Patient Change ◽  
Female Cancer Survivors ◽  
History Of Cancer

8507 Background: Problems with sexual functioning are an issue negatively affecting the quality of life of female cancer survivors. Testosterone has been implicated as an important hormone in sexual functioning such as libido. Studies of transdermal testosterone have shown benefit in enhancing libido in women who have been diagnosed with hypoactive sexual desire disorder after bilateral oophorectomy. This phase III placebo-controlled clinical trial evaluated whether transdermal testosterone would increase libido in female cancer survivors. Methods: Women with a history of cancer, currently without evidence of disease, were eligible if they reported a decrease in sexual desire and had a sexual partner. Women must have been postmenopausal. Eligible women were randomized to receive 2% testosterone in Vanicream (10 mg daily) versus placebo Vanicream for four weeks, then crossed over to the opposite treatment. The primary endpoint, libido, was measured via the desire subscales of the Changes in Sexual Functioning Questionnaire (CSFQ), which were completed at baseline and at the end of 4 and 8 weeks of treatment. The primary endpoint was the average intra-patient change from baseline to four weeks in the CSFQ subscales between the two arms. A total of 64 patients per group were needed to provide 80% power to detect a difference of 8 units between the treatment means. Two-sided alternative hypothesis testing and a 5% Type I error rate were used. Results: One hundred fifty women were enrolled onto this study. Complete data were available for 132 women. For those on active testosterone cream, serum bioavailable testosterone levels increased significantly over placebo, with a mean change from baseline of 12 and 10 ng/dl for the first and second period, respectively (p<.0001). The average intra-patient change from baseline to week 4 in libido was 5.5 on testosterone and 4.4 on placebo (p=0.58). No carryover effect was detected. The difference in average intra-patient changes from baseline for the entire crossover design between the two arms was only 1.1 points (95% confidence interval of -1.2 to 3.4, p=0.35). Conclusion: Testosterone is not a panacea for libido troubles in women with a history of cancer. Further studies are needed to determine whether there is a role for transdermal testosterone in this population. No significant financial relationships to disclose.

Smoking and binge drinking among cancer survivors: The forth Korean national health and nutrition examination surveys (KNHANES IV, 2007-2009).

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 28-28
Author(s):  
Mi Ah Han ◽  
Myeung Guen Oh ◽  
Jong Park ◽  
So Yeon Ryu ◽  
Seong Woo Choi
Keyword(s):  
Cancer Survivors ◽  
Binge Drinking ◽  
Chronic Diseases ◽  
National Health ◽  
Smoking Rate ◽  
Control Groups ◽  
Cross Sectional ◽  
Health And Nutrition ◽  
History Of ◽  
History Of Cancer

28 Background: This study aimed to describe the prevalence of smoking and binge drinking among cancer survivors in Korea, and to compare these rates with those of two control groups: individuals without a history of cancer but with other chronic diseases, and individuals without a history of cancer and without other chronic diseases. Methods: The study is a cross-sectional analysis of 37,878 adults ≥20 years old who participated in the Forth Korean National Health and Nutrition Examination Surveys (KNHANES IV, 2007-2009). The prevalence of smoking and binge drinking were assessed and compared to two control groups. Logistic regression analyses were performed to determine the likelihood and predictors of current smoking and binge drinking. Results: The prevalence of smoking and binge drinking were 9.6% and 6.6% among cancer survivors, respectively. Cancer survivors showed lower smoking rate compared with both control groups after adjusting gender, age, marital status, education, income and health insurance. Survivors’ smoking and binge drinking did not vary substantially by the clinical factors assessed. Conclusions: In our study, the smoking rate was significantly low in cancer survivor compared with both control groups. This result suggested that cancer survivors were more likely than individuals without a cancer history to obtain good health related behavior.

scholarly journals Evaluation of Health Perceptions And Healthcare Utilization Among Population-Based Female Cancer Survivors And Cancer-Free Women

2021 ◽  
Author(s):  
Kate E Dibble ◽  
Maneet Kaur ◽  
Junrui Lyu ◽  
Avonne E Connor
Keyword(s):  
Health Status ◽  
Cancer Survivors ◽  
Healthcare Utilization ◽  
Perceived Health ◽  
Mental Health Provider ◽  
Perceived Health Status ◽  
History Of ◽  
Race Ethnicity ◽  
Female Cancer Survivors ◽  
History Of Cancer

Abstract Purpose. Cancer survivors are more likely to report having a poor health status when compared to the general population; however, few studies have focused on the impact of cancer on perceived health status, in combination with other healthcare utilization and access outcomes, among women from disadvantaged health populations.Methods. 25,741 women with and without a history of cancer from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2016 contributed data. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression models for the associations between cancer status and healthcare utilization and access outcomes. Models were stratified by race/ethnicity, federal poverty level (FPL), education, and comorbidities. Results. A total of 2,415 (9.4%) women had a history of cancer with breast cancer as the most common site (n=704, 29.2%). While most survivors were non-Hispanic white (68.4%), 15.2% were Hispanic, 12.1% were non-Hispanic Black, and 4.3% were additional racial/ethnic groups. Survivors were 1.28 times more likely to report fair/poor perceived health status (95% CI, 1.09-1.50), 1.61 times more likely to report hospitalizations in the last year (95% CI, 1.40-1.86), and 1.37 times more likely to see a mental health provider within the last year (95% CI, 1.12-1.66) compared to controls. Race/ethnicity and FPL were the only significant effect modifiers.Conclusion. Our study identifies disparities in health status and healthcare utilization among female cancer survivors and recognizes the importance of evaluating these associations among disadvantaged health populations. These findings could inform future cancer survivorship care.

scholarly journals Use of Medications for Treating Anxiety and Depression in Cancer Survivors in the United States

2017 ◽  
Vol 35 (1) ◽  
pp. 78-85 ◽  
Author(s):  
Nikki A. Hawkins ◽  
Ashwini Soman ◽  
Natasha Buchanan Lunsford ◽  
Steven Leadbetter ◽  
Juan L. Rodriguez
Keyword(s):  
United States ◽  
Cancer Survivors ◽  
Medication Use ◽  
The United States ◽  
Population Based ◽  
Anxiety And Depression ◽  
Current Medication ◽  
History Of ◽  
Interview Survey ◽  
History Of Cancer

Purpose This study used population-based data to estimate the percentage of cancer survivors in the United States reporting current medication use for anxiety and depression and to characterize the survivors taking this type of medication. Rates of medication use in cancer survivors were compared with rates in the general population. Methods We analyzed data from the National Health Interview Survey, years 2010 to 2013, identifying cancer survivors (n = 3,184) and adults with no history of cancer (n = 44,997) who completed both the Sample Adult Core Questionnaire and the Adult Functioning and Disability Supplement. Results Compared with adults with no history of cancer, cancer survivors were significantly more likely to report taking medication for anxiety (16.8% v 8.6%, P < .001), depression (14.1% v 7.8%, P < .001), and one or both of these conditions combined (19.1% v 10.4%, P < .001), indicating that an estimated 2.5 million cancer survivors were taking medication for anxiety or depression in the United States at that time. Survivor characteristics associated with higher rates of medication use for anxiety included being younger than 65 years old, female, and non-Hispanic white, and having public insurance, a usual source of medical care, and multiple chronic health conditions. Survivor characteristics associated with medication use for depression were largely consistent with those for anxiety, with the exceptions that insurance status was not significant, whereas being widowed/divorced/separated was associated with more use. Conclusion Cancer survivors in the United States reported medication use for anxiety and depression at rates nearly two times those reported by the general public, likely a reflection of greater emotional and physical burdens from cancer or its treatment.

Cancer survivors with multiple chronic conditions: A rising challenge—Trend analysis from National Health Interview Survey.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e24089-e24089
Author(s):  
Changchuan Jiang ◽  
Haowei Wang ◽  
Qian Wang ◽  
Binbin Zheng ◽  
Charles L. Shapiro
Keyword(s):  
Public Health ◽  
Risk Factors ◽  
Cancer Survivors ◽  
Chronic Conditions ◽  
National Health Interview Survey ◽  
Heart Diseases ◽  
Multiple Chronic Conditions ◽  
History Of ◽  
Interview Survey ◽  
History Of Cancer

e24089 Background: Cancer survivors are disproportionally influenced by chronic/comorbid diseases, which were linked to more psychological distress, increased healthcare service use, higher medical costs, adverse clinical outcomes, and financial hardship in cancer survivors. However, the trend in chronic diseases remains unknown among cancer survivors. Methods: We conducted a population-based study using serial samples of the National Health Interview Survey (NHIS) from 2002 through 2018. The outcomes include hypertension, diabetes, stroke, coronary artery disease (angina pectoris, coronary heart disease, heart attack), other heart diseases, COPD (emphysema, chronic bronchitis in the past 12 month), hepatitis, arthritis, morbid obesity (BMI > 40 or BMI > 35 with obesity-related diseases), asthma attack within 12 months, weak/failing kidney, any liver disease. We included adults who 1) have a history of cancer for except non-melanoma skin cancer; 2) report outcomes of diseases. Multiple chronic conditions(MCC) were defined as three or more non-cancer chronic conditions. Multivariable logistics regression was used to estimate the annual percent change(APC) in prevalence from 2002 to 2018, using SAS 9.4 and accounting for the design of NHIS. Results: 30728 adult cancer survivors and 485233 adults without a history of cancer were included in the final analysis. We found increasing prevalence in hypertension, diabetes, kidney disease, liver diseases and morbid obesity from 2002 to 2018, and decreasing prevalence in heart diseases, COPD, and hepatitis. The prevalence of MCC increased significantly in cancer survivors from 23.6% in 2002 to 29.6% in 2018 (APC 0.9%, p trend < 0.01). This was especially evident in younger patients aged 18 to 44 (APC 4.4%, p trend < 0.01) and African-American patients (APC 2.2%, p trend = 0.01). Conclusions: Our findings suggest that comorbid illnesses, especially MCC, have become an emerging public health burden for cancer survivors, which requires attention and more effective risk factors interventions. Future studies are needed to identify a better strategy to modify risk factors and prevent long term comorbidities for cancer survivors. It is also important to call for public health planning given severe chronic diseases burden for this rapid-growing but vulnerable community.

Likelihood of Smoking Among Cancer Survivors: An Updated Health Information National Trends Survey Analysis

2019 ◽  
Vol 21 (12) ◽  
pp. 1636-1643 ◽  
Author(s):  
Christine M Swoboda ◽  
Daniel M Walker ◽  
Timothy R Huerta
Keyword(s):  
Cervical Cancer ◽  
High Risk ◽  
Cancer Survivors ◽  
Tobacco Dependence ◽  
Current Smoking ◽  
Education Levels ◽  
History Of ◽  
Lower Education ◽  
National Trends ◽  
History Of Cancer

Abstract Introduction Cancer survivors are at high risk for cancer reoccurrence, highlighting the importance of managing behavioral risk factors for cancer. Despite this risk, many cancer survivors continue to smoke cigarettes. This article describes the relationship between smoking behavior and demographic and clinical factors in cancer survivors. Methods Multinomial logistic regression of cross-sectional data from the Health Information National Trends Survey was conducted using combined data from years 2003, 2005, 2007, 2011, 2012, 2013, and 2014. Independent variables included age, cancer history, race, education level, marital status, insurance status, and data year; the dependent variable was smoking status (current vs. former or never). Results Cancer survivors were less likely to be current smokers but more likely to be former smokers than those with no history of cancer. Cancer survivors that currently smoked were more likely to have lower education levels, be divorced, separated, or single, or not have health insurance. Older cancer survivors, Hispanic, and non-Hispanic black survivors were less likely to smoke. Among cancer subgroups, prostate cancer survivors had the lowest rate (8.8%) of current smoking from 2011 to 2014, and cervical cancer survivors had the highest rate (31.1%). Conclusions Although those with no history of cancer had higher rates of current smoking, many subgroups of cancer survivors continued to smoke at higher rates than average cancer survivors. Cancer survivors that were younger, had lower education levels, were any marital status other than married or widowed, were uninsured, or survived cervical cancer were more likely to be smokers than other survivors. Implications It is important to understand which types of cancer survivors are at high risk of continued smoking to better inform tobacco dependence treatment interventions among those at high risk of cancer reoccurrence. Our findings suggest targeted tobacco dependence treatment efforts among cancer survivors should focus on survivors of cervical cancer and survivors that are young, unmarried, uninsured, or have lower education levels.

scholarly journals COGNITIVE FUNCTIONING AMONG BREAST CANCER SURVIVORS AND NON-CANCER PARTICIPANTS: EVIDENCE FOR SIMILARITIES

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S649-S650
Author(s):  
Giancarlo Pasquini ◽  
Brent J Small ◽  
Jacqueline Mogle ◽  
Martin Sliwinski ◽  
Stacey B Scott
Keyword(s):  
Breast Cancer ◽  
Working Memory ◽  
Executive Functioning ◽  
Cancer Survivors ◽  
Cognitive Functioning ◽  
Processing Speed ◽  
Breast Cancer Survivors ◽  
Cancer History ◽  
History Of ◽  
History Of Cancer

Abstract Breast cancer survivors may experience accelerated decline in cognitive functioning compared to same-aged peers with no cancer history (Small et al., 2015). Survivors may show important differences in mean-level performance or variability in cognitive functioning compared to those without a history of cancer (Yao et al., 2016). This study compared ambulatory cognitive functioning in a sample of breast cancer survivors and an age-matched community sample without a history of cancer (n_cancer=47, n_non-cancer=105, age range: 40-64 years, M=52.13 years). Participants completed three cognitive tasks measuring working memory, executive functioning, and processing speed up to five times per day for 14 days. Results indicated no mean-level differences in cognitive performance on the three tasks between cancer survivors and those without cancer history (p’s&gt;.05). Unexpectedly, women without cancer history showed more variability than survivors on working memory but not on the other two tasks. Across both groups, those without a college education performed worse on executive functioning (B=-0.05, SE=0.03, p&lt;.05) and working memory (B=0.94, SE=0.36, p&lt;.05) compared to those that completed college. Additionally, older age was associated with slower processing speed (B=31.67, SE=7.44, p&lt;.001). In sum, this study did not find mean-level group differences in cognitive functioning between cancer survivors and age-matched women without a history of cancer. Contrary to hypotheses, those without a history of cancer were more variable on working memory. Results suggested similarities in cognitive functioning in the two samples and that education and age are important predictors of cognitive functioning independent of cancer history.

Impact of individual- and area-level race/ethnicity on illness intrusiveness among cancer survivors

2019 ◽  
Vol 9 (6) ◽  
pp. 1208-1215
Author(s):  
Corinne R Leach ◽  
Rhyan N Vereen ◽  
Arthi V Rao ◽  
Katherine Ross ◽  
Michael A Diefenbach
Keyword(s):  
Cancer Survivors ◽  
Daily Life ◽  
Recent History ◽  
Illness Intrusiveness ◽  
History Of ◽  
Race Ethnicity ◽  
Cancer Experience ◽  
History Of Cancer

For many people with a recent history of cancer, their cancer experience intrudes into various aspects of daily life. The neighborhood in which one lives can impact how much cancer intrudes into their life.

scholarly journals Quality of life and mental health in breast cancer survivors compared with non-cancer controls: a study of patient-reported outcomes in the United Kingdom

2020 ◽  
Author(s):  
Helena Carreira ◽  
Rachael Williams ◽  
Harley Dempsey ◽  
Susannah Stanway ◽  
Liam Smeeth ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Primary Care ◽  
Cancer Survivors ◽  
Patient Reported Outcomes ◽  
Breast Cancer Survivors ◽  
Patient Reported ◽  
History Of ◽  
History Of Cancer

Abstract Purpose There is limited high-quality evidence on quality of life, anxiety, and depressive symptoms in breast cancer survivors and women with no history of cancer. We aimed to address this by comparing patient-reported outcomes between breast cancer survivors and women with no history of breast cancer. Methods Breast cancer survivors and women with no prior cancer were selected from the UK Clinical Practice Research Datalink GOLD primary care database, which includes population-based primary care electronic health record data. Breast cancer survivors and controls were frequency matched by age and primary care practice. Outcomes were assessed with validated instruments via postal questionnaire. Linear and logistic regression models were fitted to estimate adjusted associations between breast cancer survivorship and outcomes. Results A total of 356 breast cancer survivors (8.1 years post diagnosis) and 252 women with no prior cancer participated in the study. Compared with non-cancer controls, breast cancer survivors had poorer QoL in the domains of cognitive problems (adjusted β (aβ) = 1.4, p = 0.01), sexual function (aβ = 1.7, p = 0.02) and fatigue (aβ = 1.3, p = 0.01), but no difference in negative feelings, positive feelings, pain, or social avoidance. Breast cancer survivors had higher odds of borderline-probable anxiety (score ≥ 8) (adjusted OR = 1.47, 95%CI:1.15–1.87), but no differences in depression. Advanced stage at diagnosis and chemotherapy treatment were associated with poorer QoL. Conclusions Compared with women with no history of cancer, breast cancer survivors report more problems with cognition, sexual function, fatigue, and anxiety, particularly where their cancer was advanced and/or treated with chemotherapy. Implications for Cancer Survivors Breast cancer survivors with more advanced disease and/or treated with chemotherapy should be closely monitored and, when possible, offered evidence-based intervention for fatigue, cognitive dysfunction, and sexual problems.

Sign in / Sign up

Export Citation Format

Share Document